Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy – guidance (TA655)

Nivolumab is recommended for locally advanced or metastatic squamous non-small-cell lung cancer after chemotherapy, only if they have not had a PD‑1 or PD‑L1 inhibitor before, and it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses.

National Institute for Health and Care Excellence